Vivo Opportunity reports INM insider holdings
InMed Pharmaceuticals Inc. reported initial insider holdings for several Vivo Opportunity investment entities.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3
Rhea-AI Filing Summary
InMed Pharmaceuticals Inc. reported initial insider holdings for several Vivo Opportunity investment entities. Vivo Opportunity Cayman Fund, L.P. indirectly holds 49,679 common shares, while Vivo Opportunity Fund Holdings, L.P. indirectly holds 492,073 common shares. The general partners, Vivo Opportunity, LLC and Vivo Opportunity Cayman, LLC, each disclaim beneficial ownership except to the extent of their pecuniary interest.
Insider Trade Summary
Holdings reported, no transactions
Holdings
Insider
Vivo Opportunity, LLC, Vivo Opportunity Fund Holdings, L.P., Vivo Opportunity Cayman Fund, L.P., Vivo Opportunity Cayman, LLC
Role
10% Owner | 10% Owner | 10% Owner | 10% Owner
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Holding | Common Shares | -- | -- | -- |
| Holding | Common Shares | -- | -- | -- |
Holdings:
Common Shares — 492,073 shares (Indirect, By: Vivo Opportunity Fund Holdings, L.P.);
Common Shares — 49,679 shares (Indirect, By: Vivo Opportunity Cayman Fund, L.P.)
Footnotes (2)
- F1. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
- F2. Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
Key Figures
Indirect holdings: 49,679 shares
Indirect holdings: 492,073 shares
Unknown transactions: 2 entries
+1 more
4 metrics
Indirect holdings
49,679 shares
Common Shares held by Vivo Opportunity Cayman Fund, L.P. after transaction
Indirect holdings
492,073 shares
Common Shares held by Vivo Opportunity Fund Holdings, L.P. after transaction
Unknown transactions
2 entries
Holding entries with unknown transaction codes in transaction summary
Net buy/sell direction
neutral
Transaction summary netBuySellDirection for this Form 3
Key Terms
ten percent owner, beneficial ownership, pecuniary interest, Section 16
4 terms
ten percent owner regulatory
"is_ten_percent_owner": 1"
beneficial ownership regulatory
"disclaims beneficial ownership over such securities except to the extent"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
pecuniary interest financial
"except to the extent of its pecuniary interest therein"
Section 16 regulatory
"for purposes of Section 16 or for any other purposes"
Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does InMed Pharmaceuticals (INM) Form 3 filing by Vivo Opportunity report?
The Form 3 shows initial ownership of InMed Pharmaceuticals common shares by Vivo Opportunity-related funds. It lists indirect holdings of 49,679 shares by Vivo Opportunity Cayman Fund, L.P. and 492,073 shares by Vivo Opportunity Fund Holdings, L.P., establishing them as ten percent owners.
Are Vivo Opportunity entities ten percent owners of InMed Pharmaceuticals (INM)?
Yes, the Form 3 identifies each Vivo Opportunity reporting person as a ten percent owner. This status triggers Section 16 reporting obligations, requiring disclosure of their initial holdings and future reportable transactions in InMed Pharmaceuticals securities.
Do Vivo Opportunity, LLC and Vivo Opportunity Cayman, LLC claim beneficial ownership of INM shares?
The general partners Vivo Opportunity, LLC and Vivo Opportunity Cayman, LLC both disclaim beneficial ownership of the reported InMed shares, except to the extent of their pecuniary interest. The securities are recorded in the names of their respective limited partnership funds.
Does the InMed (INM) Form 3 show any recent buy or sell transactions?
No, the Form 3 functions as an initial ownership report and does not show explicit buy or sell transactions. The entries are classified as holdings with unknown transaction codes, focusing on share amounts held after the reporting date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
